The estimated Net Worth of Joseph J Krivulka is at least $91.3 millier dollars as of 26 June 2017. Joseph Krivulka owns over 15,000 units of Nektar Therapeutics stock worth over $91,250 and over the last 20 years Joseph sold NKTR stock worth over $0.
Joseph has made over 4 trades of the Nektar Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently Joseph exercised 15,000 units of NKTR stock worth $125,550 on 26 June 2017.
The largest trade Joseph's ever made was exercising 15,000 units of Nektar Therapeutics stock on 26 June 2017 worth over $125,550. On average, Joseph trades about 2,609 units every 31 days since 2005. As of 26 June 2017 Joseph still owns at least 73,000 units of Nektar Therapeutics stock.
You can see the complete history of Joseph Krivulka stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie et John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: